Given that increased inflammatory responses and inflammatory cell infiltration are key hallmarks of AAA pathobiology, decreased SMYD2 levels in AAA patients may facilitate disease progression via reactivation of macrophages and inflammation. This evidence concerns the gene SMYD2 and triple-A syndrome.